Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
The projected business potential is around US$ 1 million in the first year
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
Rivaroxaban is used to treat venous thromboembolism
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Subscribe To Our Newsletter & Stay Updated